Cas:917896-26-5 N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine manufacturer & supplier

Chemical Name:N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine

CAS.NO:917896-26-5

Synonyms:4-Pyrimidinamine,N-cyclopentyl-5-(4-iodophenyl)-2-methyl

Molecular Formula:C₁₆H₁₈IN₃

Molecular Weight:379.23900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:37.81000

Exact Mass:379.05500

LogP:4.48410

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Pyrimidinamine,N-cyclopentyl-5-(4-iodophenyl)-2-methyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Pyrimidinamine,N-cyclopentyl-5-(4-iodophenyl)-2-methyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Pyrimidinamine,N-cyclopentyl-5-(4-iodophenyl)-2-methyl Use and application,4-Pyrimidinamine,N-cyclopentyl-5-(4-iodophenyl)-2-methyl technical grade,usp/ep/jp grade.

Related News: This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine manufacturer Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.��s governing body. N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine supplier However, compared with the 60-70% refinement rate in developed economies such as North America, Western Europe, and Japan, China is still only equivalent to the level of the United States in the 1980s. There is still a lot of room for improvement in China’s refinement rate. period. N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine vendor This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.